CYTENA enters long term OEM supply agreement with PAIA and launches the F.QUANT Titer high-throughput titer quantification assays for antibodies and Fc fusion proteins
Twitter Facebook Linkedin Envelope The F.QUANT Titer assays enable cost-effective identification of high-producer clones for biopharmaceutical cell line development utilizing fluorescence plate readers Today CYTENA, a BICO group company (Nasdaq Stockholm: BICO) and a leading provider of high-precision instruments for handling biological cells and PAIA Biotech GmbH, a developer of assays for the rapid analysis …